JPRN-UMIN000015467已完成2 期
Phase II study of erlotinib plus bevacizumab and inserted cisplatin, pemetrexed plus bevacizumab as a 1st-line treatment for advanced non-squamous, non-small cell lung cancer harboring activating EGFR mutations - Phase II study of erlotinib plus bevacizumab and inserted cisplatin, pemetrexed plus bevacizumab as a 1st-line treatment for advanced non-small cell lung cancer harboring activating EGFR mutations
Department of Thoracic Oncology Osaka Medical Center for Cardiovascular diseases0 个研究点目标入组 20 人开始时间: 2014年10月18日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 74years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Harboring EGFR mutation of Exon20,T790M 2)Have symptomatic brain metastases or spinal metastases requiring surgical treatment or irradiation. 3)The presence of other concomitant malignancy less than 5 years disease-free interval 4)Have a pleural effusion, ascites or pericardial effusion requiring treatment 5)SVC syndrome 6)Symptomatic spinal cord compression 7)Currently have brain vascular disease with symptom, or have a history of it within one year before enrollment 8)Have sn unhealed fracture 9)Have a serious concomitant active infection 10)Have any evidence of interstitial lung on chest X-ray 11)Have a serious unstable angina, congestive heart failure, arrythmia requiring treatment and a history of myocardial infarction within 12 months prior to enrollment. 12)Clinically significant drug allergy 13)History of use of pemetrexed or EGFR-TKI as preoperative or postoperative adjuvant therapy 14)Pregnant or beeast-feeding woman or patient who doesn't agree to contraception 15) Mental disease or psychotic manifestation 16)Not suitable for participating in the study for any other reason 17)Currently have or have a history of hemoptysis 18) Patients with or with anticipation of invasive procedures as defined below: 1.Major surgery within four weeks of registration 2.two weeks after drainage tube removal 3.two weeks after pleurodesis 4.Minor surgical procedures or core biopsy within two weeks of registration etc. 19)Have a bleeding tendency 20)Have an intestinal diverticulitis 21)Have a history of gastrointestinal perforation less than one year prior to enrollment 22)Uncontrolable hypertension 23)Have a evidence of thrombosis 24)HBs antigen-positive cases Others
研究者
相似试验
已完成
2 期
A phase II study of erlotinib plus bevacizumab in patients with performance status 2 to 3 and EGFR mutation-positive advanced non-small-cell lung cancerJPRN-UMIN000016507Shizuoka cancer center21
已完成
不适用
A phase II study of erlotinib plus bevacizumab in chemo-naive patients aged 75 or older with advanced non-squamous non-small-cell lung cancer harboring sensitive EGFR gene mutations(HSR1501)Advanced non-squamous non-small-cell lung cancerJPRN-UMIN000016904Department of Internal medicine, second division, Hamamatsu Univ. School of Medicine26
尚未招募
2 期
A phase II study of Erlotinib Plus Bevacizumab in patients with advanced Non-squamous Non- Small Cell Lung Cancer with brain metastasis and Harboring Epidermal Growth Factor Receptor Mutations.on-Small-Cell Lung CancerJPRN-UMIN000012514Department of Respiratory Medicine, Kumamoto University Hospital16
尚未招募
2 期
A phase II study of Erlotinib and Bevacizumab combination therapy for previously treated III B / IV Stage non-squamous non-small cell lung cancer: IMSLC-001non-squamous non-small cell lung cancerJPRN-UMIN000011791Itabashi Chuo Medical Center16
招募中
2 期
Phase II study evaluating Erlotinib/Bevacizumab therapy as a second line therapy for advanced relapsed EGFR mutation positive non-squamous NSCLC patients who received first line combination therapy including platinum and Bevacizumabnon-squamous non-small-cell lung cancerJPRN-UMIN000009603Respiratory Center, Showa University Northern Yokohama Hospital13